Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 81Neoplasms 75Colorectal Neoplasms 65Neoplasm Metastasis 64Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 53Pancreatic Neoplasms 51Ovarian Neoplasms 50Multiple Myeloma 50Triple Negative Breast Neoplasms 36Lung Neoplasms 36Melanoma 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Glioblastoma 31Carcinoma, Renal Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Endometrial Neoplasms 28Carcinoma, Hepatocellular 28Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Myelodysplastic Syndromes 24Lymphoma, Follicular 24Lymphoma, B-Cell 24Sarcoma 23

Interventions

tebentafusp 1pembrolizumab 1fludarabine 1Interleukin-2 1Drug Therapy 1Cyclophosphamide 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Select Advanced Solid Tumors × 90 days × Clear all
NCT06598371 2026-05-20

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
141 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Immunocore Ltd

Phase 1/2 Active not recruiting
410 enrolled
Other solid neoplasm

Select Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡